Company Overview
Gland Pharma Limited (Scrip Code: 543245, NSE: GLAND) reported strong financial performance for FY 2025-26 with consolidated revenues of ₹64,307 million, representing 14.5% growth year-over-year. The company achieved EBITDA of ₹16,295 million with margin expansion to 25.34% (improved 275 bps from FY25) and Profit After Tax of ₹10,273 million with 28% increase from previous year.
Financial Performance Highlights
Standalone Performance: Revenue from operations reached ₹45,520.92 million (10.6% growth), with net profit of ₹12,995.51 million (19.2% increase). Base business performance (excluding Cenexi) showed revenue of ₹45,613 million with 11% growth and EBITDA margin of 36% (140 bps improvement).
Key Financial Ratios: Significant improvement across all metrics including Interest Coverage Ratio at 133.85 times (62% increase), Net Profit Margin at 15.98% (28% increase), Return on Net Worth at 10.53% (35% increase), and Return on Capital Employed at 11.49% (22% increase).
Dividend Declaration: The Board recommended a final dividend of ₹20 per equity share (2000% on face value of ₹1) subject to shareholder approval at the 48th AGM scheduled for August 25, 2026. Record date for dividend entitlement is August 11, 2026.
Strategic Business Developments
The company expanded its CDMO business with multiple GLP-1 partnerships for semaglutide and liraglutide programs, increasing cartridge fill-finish capacity from 40 million to 140 million units. The strategic acquisition of Cenexi marked a significant milestone in expanding global CDMO footprint with operations across France and Belgium, involving transformation initiatives including streamlining operations, improving OEE, and capacity expansion.
Operational and Market Performance
Geographic Revenue Mix: USA contributed 53% of revenue (₹34,214 million, 13% growth), Europe 22% (₹14,035 million, 34% growth), India 4% (₹2,672 million, 7% growth), with exports accounting for 88.44% of total turnover.
Business Model Performance: IP led - Own ANDA B2B contributed 32% (₹20,358 million, 10% growth), IP led - Partner ANDA B2B 21% (₹13,657 million, -2% growth), and Tech Transfer B2B 46% (₹29,401 million, 29% growth).
Corporate Governance and Leadership
Board Composition: 8 Directors (1 Executive, 3 Non-Executive, 4 Independent) with 6 meetings held during FY26. Key management changes included Mr. Shyamakant Giri's resignation as CEO and Dr. Jitendra Gangwal's appointment as Head - R&D.
Director Reappointments: Mr. Wenjie Zhang and Ms. Wei Huang proposed for reappointment at AGM. Independent Directors Ms. Naina Lal Kidwai and Mr. Essaji Goolam Vahanvati were reappointed for second terms.
Remuneration Disclosure: Executive Chairman Mr. Srinivas Sadu received 233.24 times median remuneration with 71.53% increase, while CEO Mr. Shyamakant Giri saw 237.04% increase (not annualized as appointed mid-year).
ESG and Sustainability Metrics
The company reported comprehensive BRSR metrics with 4,332 employees, energy from renewable sources at 15.77%, R&D investment of ₹2,230 million (5% of base business revenue), and CSR contribution of ₹261.36 million. Safety performance showed zero fatalities and zero lost time injuries.
Exceptional Items and Provisions
The company incurred an exceptional item of ₹243.46 million for additional provision towards employee benefits (gratuity ₹171.80 million and leave liability ₹71.66 million) due to implementation of new Labor Codes effective November 21, 2025.
Subsidiary Structure and Investments
Material subsidiaries include Gland Pharma International Pte Ltd (Singapore, 100% owned) and Phixen SAS with its subsidiaries (Cenexi Group, France, 100% owned). The company invested ₹32,925.52 million in subsidiaries and made capital expenditure of ₹4,938 million towards expanding production lines.
Regulatory Compliance and Governance
The company complied with all SEBI Listing Regulations, Companies Act 2013 requirements, and conducted its 48th AGM virtually via VC/OAVM with detailed e-voting instructions through NSDL platform. No material penalties or strictures were imposed by regulatory authorities during FY26.
Forward Outlook
Gland Pharma continues to strengthen its position in sterile injectables and CDMO business with expanded global footprint, enhanced manufacturing capabilities, and strategic partnerships positioning the company for sustained growth in FY27 and beyond.